INVESTOR RELATIONS
OVERVIEW
Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease.
Market Listings For Amarin Stock
Amarin is listed on the Nasdaq capital market (ticker: AMRN).
INVESTOR RELATIONS
Recent News
more >>
INVESTOR RELATIONS
Investor Relations Contacts
|
Amarin Corporation plc |
Company Registrars
| Lloyds TSB Registrars, The Causeway, Worthing, West Sussex BN99 6DA, UK |
Citibank,
|
This page was last updated on July, 1 2008.
